Skip to main content
SpringerLink
Log in

Therapeutic Approaches to Metastatic Bone Cancer II: Targeted and Non-targeted Systemic Agents

  • Chapter
  • First Online:
Bone and Cancer

Part of the book series: Topics in Bone Biology ((TBB,volume 5))

  • 968 Accesses

Abstract

Skeletal metastases occur most commonly in the advanced stages of prostate, breast, and lung cancer, but also can occur in thyroid cancer and renal cell carcinoma (RCC) [22]. The skeleton is the third most common organ affected by metastases from these solid tumors [17]. In general, bone metastases disrupt normal bone remodeling to cause either osteolytic or osteoblastic bone lesions. Metastatic breast cancer and renal cell cancer are often associated with osteolytic bone lesions. Prostate cancer is associated primarily with osteoblastic lesions [8]. Bone metastases cause significant morbidity, including pain, hypercalcemia, pathologic fractures, and spinal cord or nerve root compression. Bone metastases can occasionally lead to life-threatening complications, and most commonly do so for patients with bone metastases from breast and lung cancer [17].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ain KB, Egorin MJ, and DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10: 587–594 (2000).

    CAS  Google Scholar 

  2. Anderson P and Nunez R. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther. 7(11): 1517–1527 (2007).

    Article  Google Scholar 

  3. Atkins MB, Hidalgo M, Stadler W et al. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc clin Oncol 2002; abstr 36.

    Google Scholar 

  4. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 1: 18–23 (2007).

    Article  Google Scholar 

  5. Beer, TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96: 508–13 (2005).

    Article  PubMed  CAS  Google Scholar 

  6. Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21: 123–8 (2003).

    Article  PubMed  CAS  Google Scholar 

  7. Bollag G, Freeman S, Lyons JF et al. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 4: 1436–41 (2003).

    PubMed  CAS  Google Scholar 

  8. Brown SA, Clines GA, and Guise TA. Local effects of malignancy on bone. Curr Opin Endocrinol diabetes Obes 14: 436–441 (2007).

    Google Scholar 

  9. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER-2 positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (Epub ahead of print) (2008, Feb 17).

    Google Scholar 

  10. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008 Jan11 (Epub ahead of print).

    Google Scholar 

  11. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6): 713–8 (2007).

    Article  PubMed  CAS  Google Scholar 

  12. Cohen R, Quidville V, and Bihan H. Medullary carcinoma and hormones. Ann Med Interne 154(2): 109–116 (2003).

    CAS  Google Scholar 

  13. Dolezl J, Vizda J, and Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int 78: 50–57 (2007).

    Article  Google Scholar 

  14. Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 1030: 69–77 (2004).

    Article  PubMed  CAS  Google Scholar 

  15. Ernst DS, Tannock IF, Winquist EW et al. Randomized double-blind trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335–3342 (2003).

    Article  PubMed  CAS  Google Scholar 

  16. Eseudier B, Szezylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:16S (abstract 4510) (2005).

    Google Scholar 

  17. Facchini G, Caraglia M, Santini D et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res 26, 3: 307–312 (2007).

    Google Scholar 

  18. Johnson SR and Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc.) 42(7): 441–53 (2006, Jul).

    Article  Google Scholar 

  19. Kvinlaug BT, Huntly BJP. Expert Opin Ther Targets 11(7): 915–927 (2007).

    Article  PubMed  CAS  Google Scholar 

  20. Lassiter LK and Carducci MA. Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol 30:678–88 (2003).

    Article  Google Scholar 

  21. Le Gall C, Bellahcene A, and Bonnelye E. A Cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden. Cancer Res 67(20): 9894–9902 (2007).

    Article  PubMed  Google Scholar 

  22. Li F, Toed B, et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17: 3–14 (2007).

    Article  PubMed  CAS  Google Scholar 

  23. Liepe K and Kotzerke J. A comparative study of 188Re-HEDP, 186-HEDP, 153Sm-EDTMP, and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28:623–630 (2007).

    Article  PubMed  CAS  Google Scholar 

  24. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J. Med 357 (26): 2666–76 (2007, Dec 27).

    Article  PubMed  CAS  Google Scholar 

  25. Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91: 4013–4121 (2006).

    Article  PubMed  CAS  Google Scholar 

  26. Moley JF and Fialkowski EA. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31: 946–956 (2007).

    Article  PubMed  Google Scholar 

  27. Morgan C, Lewis PD, and Jones RM. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46: 669–677 (2007).

    Article  PubMed  CAS  Google Scholar 

  28. Motzer RJ, Rini BI, Michaelson MD et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc ASCO Post-Meeting Edition, J Clin Oncol 22 (suppl 15:4500) (2004).

    Google Scholar 

  29. Muenchen HJ, POncza PJ, and Pienta KJ. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 57: 366–70 (2001).

    Article  PubMed  CAS  Google Scholar 

  30. Patel KN and Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13(2): 119–128 (2006).

    PubMed  Google Scholar 

  31. Peleg S. Responsiveness of osteoblastic and osteolytic bone metastases to vitamin D analogs. Crit Rev Eukaryot Gene Expr 17(2): 149–158 (2007).

    PubMed  CAS  Google Scholar 

  32. Sakurai K, Enomoto K, Kitajima A et al. Efficacy of trastuzumab alone therapy compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancer. Gan To Kagaku Ryoho 34(12): 1911–3 (2007).

    PubMed  Google Scholar 

  33. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful bone disease. Int J Radiat Oncol Biol Phys 30: 1187–1194 (1994)

    PubMed  CAS  Google Scholar 

  34. Sharkey RM, Hajjar G, Yeldell D et al. A phase I trial combining high-dose 90Y-labelled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem-cell rescue in advanced medullary thyroid cancer. J Nucl Med 46: 620–633 (2005).

    PubMed  CAS  Google Scholar 

  35. Staehler M, Rohrmann K, Haseke N, et al. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6: 835–846 (2005).

    Article  PubMed  CAS  Google Scholar 

  36. Sugiura H, Yamad K, Sugiura T et al. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466(3): 729–3 (2008)

    Article  PubMed  Google Scholar 

  37. Tamura K, Okamoto I, Kashii T et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (Epub ahead of print) (2008, Feb 19).

    Google Scholar 

  38. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for advanced prostate cancer. N Engl J. Med 351: 1502–12 (2004).

    Article  PubMed  CAS  Google Scholar 

  39. Tsuya A, Kurata T, Tamura K et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57: 229–232 (2007).

    Article  PubMed  Google Scholar 

  40. Van Nostrand D, Atkins F, Yeganeh F et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12: 121–34 (2002).

    Article  PubMed  Google Scholar 

  41. Van Spronsen DJ and De Mulder PHM. Targeted approaches for treating advanced clear cell renal carcinoma. Onkologie 29:394–402 (2006).

    Article  PubMed  Google Scholar 

  42. Voigt W, Kegel T, Weis M et al. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131: 585–590 (2005).

    Article  PubMed  CAS  Google Scholar 

  43. Woodward JKL, Holen I, Coleman RE et al. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone 41: 912–927 (2007).

    Article  PubMed  CAS  Google Scholar 

  44. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, and anti-vascular endothelial growth fact antibody, for metastatic renal cancer. N Engl J Med 349: 427–34 (2003).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, Delaware, USA

    Stephen S. Grubbs & Charles J. Schneider

Authors
  1. Stephen S. Grubbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles J. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag London

About this chapter

Cite this chapter

Grubbs, S.S., Schneider, C.J. (2010). Therapeutic Approaches to Metastatic Bone Cancer II: Targeted and Non-targeted Systemic Agents. In: Bone and Cancer. Topics in Bone Biology, vol 5. Springer, London. https://doi.org/10.1007/978-1-84882-019-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-019-7_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-018-0

  • Online ISBN: 978-1-84882-019-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation